Does plasma level of mycophenolate mofetil correlate with its gastrointestinal side effects?
- Conditions
- Health Condition 1: N186- End stage renal disease
- Registration Number
- CTRI/2018/09/015853
- Lead Sponsor
- PGIMER Chandigarh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients above 18 years of age of either sex
2.Patients who have undergone de novo renal transplantation in the past two weeks (15 days) and have been started on MMF (CELLCEPT) at a dose of 1 g twice a day
1.Patients undergoing multi-organ transplantation
2.Patients harbouring HIV, Hepatitis B or C infections
3.Patients suffering from any malignancy requiring recent surgery, ongoing chemotherapy or radiation
4.Patients suffering from any acute systemic infections within 30 days prior to enrolment
5.Patients who had received any investigational drug within past 6 months
6.Pregnant, nursing mothers or women of childbearing potential without an effective method of birth control
7.Patients who are started on enteric coated mycophenolate sodium (EC-MPS)
8.Patients not willing to participate in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method